小分子赖氨酰氧化酶样2（LOXL2）抑制剂：一种对LOXL2具有选择性而非LOX的抑制剂的鉴定。
Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.
作者信息
Hutchinson John H, Rowbottom Martin W, Lonergan David, Darlington Janice, Prodanovich Pat, King Christopher D, Evans Jilly F, Bain Gretchen
机构信息
PharmAkea Inc., 3030 Bunker Hill Street, Suite 300, San Diego, California 92109, United States.
出版信息
ACS Med Chem Lett. 2017 Mar 1;8(4):423-427. doi: 10.1021/acsmedchemlett.7b00014. eCollection 2017 Apr 13.
Abstract
Two series of novel LOXL2 enzyme inhibitors are described: benzylamines substituted with electron withdrawing groups at the -position and 2-substituted pyridine-4-ylmethanamines. The most potent compound, (2-chloropyridin-4-yl)methanamine (hLOXL2 IC = 126 nM), was shown to be selective for LOXL2 over LOX and three other amine oxidases (MAO-A, MAO-B, and SSAO). Compound is the first published small molecule inhibitor selective for LOXL2 over LOX.
摘要
描述了两类新型赖氨酰氧化酶2（LOXL2）酶抑制剂：在α位被吸电子基团取代的苄胺和2-取代吡啶-4-基甲胺。最有效的化合物（2-氯吡啶-4-基）甲胺（人LOXL2的半数抑制浓度[IC] = 126 nM）对LOXL2具有选择性，相对于赖氨酰氧化酶（LOX）以及其他三种胺氧化酶（单胺氧化酶A[MAO-A]、单胺氧化酶B[MAO-B]和二胺氧化酶[SSAO]）。化合物是首个发表的对LOXL2比对LOX具有选择性的小分子抑制剂。
相似文献
1
Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.小分子赖氨酰氧化酶样2（LOXL2）抑制剂：一种对LOXL2具有选择性而非LOX的抑制剂的鉴定。
ACS Med Chem Lett. 2017 Mar 1;8(4):423-427. doi: 10.1021/acsmedchemlett.7b00014. eCollection 2017 Apr 13.
2
LOXL2 Inhibitors and Breast Cancer Progression.赖氨氧化酶样蛋白2（LOXL2）抑制剂与乳腺癌进展
Antioxidants (Basel). 2021 Feb 19;10(2):312. doi: 10.3390/antiox10020312.
3
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).鉴定4-（氨甲基）-6-（三氟甲基）-2-（苯氧基）吡啶衍生物为铜依赖性胺氧化酶赖氨酰氧化酶样2（LOXL2）的强效、选择性和口服有效的抑制剂。
J Med Chem. 2017 May 25;60(10):4403-4423. doi: 10.1021/acs.jmedchem.7b00345. Epub 2017 May 15.
4
Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2.威尔逊病中肝细胞周围胶原蛋白的异常沉积与赖氨酰氧化酶和赖氨酰氧化酶样蛋白-2的肝细胞特异性表达有关。
J Hepatol. 2005 Sep;43(3):499-507. doi: 10.1016/j.jhep.2005.02.052.
5
LOXL2 small molecule inhibitor restrains malignant transformation of cervical cancer cells by repressing -induced epithelial-mesenchymal transition (EMT).LOXL2 小分子抑制剂通过抑制 β-catenin 诱导的上皮-间充质转化（EMT）来抑制宫颈癌细胞的恶性转化。
Cell Cycle. 2022 Sep;21(17):1827-1841. doi: 10.1080/15384101.2022.2073047. Epub 2022 May 11.
6
Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.小分子赖氨酰氧化酶样蛋白2（LOXL2）抑制剂在乳腺癌中的临床前评估
Oncotarget. 2017 Apr 18;8(16):26066-26078. doi: 10.18632/oncotarget.15257.
7
Purification of enzymatically active human lysyl oxidase and lysyl oxidase-like protein from Escherichia coli inclusion bodies.从大肠杆菌包涵体中纯化具有酶活性的人赖氨酰氧化酶和类赖氨酰氧化酶蛋白。
Protein Expr Purif. 2003 Oct;31(2):240-6. doi: 10.1016/s1046-5928(03)00217-1.
8
Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3.赖氨酸氧化酶样蛋白 2/3 的基于机制的氟烯丙胺抑制剂的鉴定和优化。
J Med Chem. 2019 Nov 14;62(21):9874-9889. doi: 10.1021/acs.jmedchem.9b01283. Epub 2019 Oct 16.
9
Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis.赖氨酰氧化酶样蛋白 2（LOXL2）在胆汁淤积中调节胆管细胞的屏障功能。
J Hepatol. 2018 Aug;69(2):368-377. doi: 10.1016/j.jhep.2018.04.009. Epub 2018 Apr 28.
10
The role of LOX and LOXL2 in scar formation after glaucoma surgery.LOX 和 LOXL2 在青光眼手术后瘢痕形成中的作用。
Invest Ophthalmol Vis Sci. 2013 Aug 27;54(8):5788-96. doi: 10.1167/iovs.13-11696.
引用本文的文献
1
Leveraging the Tumor Microenvironment as a Target for Cancer Therapeutics: A Review of Emerging Opportunities.利用肿瘤微环境作为癌症治疗靶点：新兴机遇综述
Pharmaceutics. 2025 Jul 29;17(8):980. doi: 10.3390/pharmaceutics17080980.
2
Beyond classical collagen: basement membrane collagen IV in age-associated lung diseases.超越经典胶原蛋白：年龄相关性肺部疾病中的基底膜胶原蛋白IV
Eur Respir Rev. 2025 Jul 23;34(177). doi: 10.1183/16000617.0192-2024. Print 2025 Jul.
3
An in vitro model to measure the strength and stiffness of the extracellular matrix synthesized de novo by human fibroblasts.一种用于测量人成纤维细胞从头合成的细胞外基质的强度和刚度的体外模型。
In Vitro Model. 2025 Mar 7;4(1):59-69. doi: 10.1007/s44164-025-00081-y. eCollection 2025 Feb.
4
Biomechanical Properties and Cellular Responses in Pulmonary Fibrosis.肺纤维化中的生物力学特性与细胞反应
Bioengineering (Basel). 2024 Jul 24;11(8):747. doi: 10.3390/bioengineering11080747.
5
LOXL2 inhibition ameliorates pulmonary artery remodeling in pulmonary hypertension.LOXL2 抑制可改善肺动脉高压中的肺动脉重构。
Am J Physiol Lung Cell Mol Physiol. 2024 Oct 1;327(4):L423-L438. doi: 10.1152/ajplung.00327.2023. Epub 2024 Jul 16.
6
The role of LOXL2 in tumor progression, immune response and cellular senescence: a comprehensive analysis.赖氨酰氧化酶样蛋白2（LOXL2）在肿瘤进展、免疫反应和细胞衰老中的作用：一项综合分析。
Discov Oncol. 2024 Jun 26;15(1):245. doi: 10.1007/s12672-024-01107-9.
7
Skeletal Muscle SIRT3 Deficiency Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction.骨骼肌 SIRT3 缺乏导致射血分数保留的心力衰竭相关肺动脉高压的肺血管重构。
Circulation. 2024 Sep 10;150(11):867-883. doi: 10.1161/CIRCULATIONAHA.124.068624. Epub 2024 May 28.
8
Targets in the Tumour Matrisome to Promote Cancer Therapy Response.肿瘤基质组中促进癌症治疗反应的靶点。
Cancers (Basel). 2024 May 11;16(10):1847. doi: 10.3390/cancers16101847.
9
On-Resin Photochemical Decarboxylative Arylation of Peptides.树脂上光化学脱羧芳基化肽。
Org Lett. 2024 Apr 12;26(14):2795-2799. doi: 10.1021/acs.orglett.3c03070. Epub 2023 Oct 11.
10
LOXL2 in Cancer: A Two-Decade Perspective.LOXL2 在癌症中的作用：二十年的研究视角。
Int J Mol Sci. 2023 Sep 21;24(18):14405. doi: 10.3390/ijms241814405.
本文引用的文献
1
Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.小分子赖氨酰氧化酶样蛋白2（LOXL2）抑制剂在乳腺癌中的临床前评估
Oncotarget. 2017 Apr 18;8(16):26066-26078. doi: 10.18632/oncotarget.15257.
2
Lysyl oxidase-like 2 (LOXL2) oxidizes trimethylated lysine 4 in histone H3.赖氨酰氧化酶样蛋白2（LOXL2）可氧化组蛋白H3中三甲基化的赖氨酸4。
FEBS J. 2016 Dec;283(23):4263-4273. doi: 10.1111/febs.13922. Epub 2016 Oct 30.
3
Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial.西马珠单抗治疗HIV和HCV感染成人的晚期肝纤维化：一项6个月开放标签安全性试验的结果。
Liver Int. 2016 Dec;36(12):1783-1792. doi: 10.1111/liv.13177. Epub 2016 Jul 6.
4
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives.特发性肺纤维化的药物治疗：当前方法、未解决问题及未来展望
Biomed Res Int. 2015;2015:329481. doi: 10.1155/2015/329481. Epub 2015 Dec 8.
5
Origin and evolution of lysyl oxidases.赖氨酰氧化酶的起源与进化。
Sci Rep. 2015 May 29;5:10568. doi: 10.1038/srep10568.
6
Human lysyl oxidase-like 2.人赖氨酰氧化酶样蛋白2
Bioorg Chem. 2014 Dec;57:231-241. doi: 10.1016/j.bioorg.2014.07.003. Epub 2014 Aug 1.
7
A new role for LOX and LOXL2 proteins in transcription regulation.赖氨氧化酶（LOX）和赖氨氧化酶样蛋白2（LOXL2）在转录调控中的新作用。
FEBS J. 2015 May;282(9):1768-73. doi: 10.1111/febs.12961. Epub 2014 Sep 6.
8
Human copper-dependent amine oxidases.人铜依赖胺氧化酶。
Arch Biochem Biophys. 2014 Mar 15;546:19-32. doi: 10.1016/j.abb.2013.12.022. Epub 2014 Jan 6.
9
Novel pyridazinone inhibitors for vascular adhesion protein-1 (VAP-1): old target-new inhibition mode.新型哒嗪酮类血管黏附蛋白-1（VAP-1）抑制剂：老靶点新抑制模式。
J Med Chem. 2013 Dec 27;56(24):9837-48. doi: 10.1021/jm401372d. Epub 2013 Dec 13.
10
Matrix regulation of idiopathic pulmonary fibrosis: the role of enzymes.特发性肺纤维化的基质调节：酶的作用
Fibrogenesis Tissue Repair. 2013 Nov 26;6(1):20. doi: 10.1186/1755-1536-6-20.
Zotero 插件